Home » Newsletters » BioWorld Science

BioWorld Science

July 18, 2019

View Archived Issues

Microglia and AD

BRCA's effects range from indispensable to indifferent

Mimicking bone marrow keeps cultured blood stem cells quiescent

Polyphor closes phase III PRISM studies of murepavadin intravenous formulation

Positive topline data presented from phase IIb study of the TLPLDC vaccine

Recruitment ongoing in phase I/II study of FT-4101 in overweight/obese subjects with NASH

Tipepidine shows promise as a supplementary medication in children with ADHD

PledPharma reports results from POP phase I trial of calmangafodipir for paracetamol overdose

Results of exploratory analysis based on tumor location from phase II REACHIN study of regorafenib

Anti-SEMA4D antibody VX-15 may offer therapeutic potential for Alzheimer's disease

Intracutaneous zolmitriptan given high Migraine-ACT scores in clinical trial

Researchers test intranasal dantrolene for the treatment of Alzheimer's disease

X4 Pharmaceuticals patents CXCR4 antagonists

Bellus Health initiates phase II trial of BLU-5937 for unexplained or refractory chronic cough

Sterngreene presents new EGFR and HER2 inhibitors

Cyclerion Therapeutics synthesizes sGC activators

Presentation of data for PLX-R18 as prophylactic countermeasure for ARS

WHO declares Ebola outbreak in DRC a public health emergency of international concern

ChemoCentryx describes C5aR antagonists

Ribon Therapeutics discovers PARP14 inhibitors

Seelos submits IND for phase IIb/III study of SLS-005 for Sanfilippo syndrome

Cognitive and motor function enhanced by ASKT-4290 in aged mice

Apellis to develop APL-9 to target host responses to AAV vector administration

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...